Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

The World Health Organisation (WHO) classifies Buruli ulcer as one of 17 Neglected Tropical Diseases (NTDs) affecting more ...

A doctor has explained how to tell whether you have Covid or the flu, with the latest symptoms as new strains of coronavirus ...

Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 ...

Market expert Raja Venkatraman shares his top three stocks to buy today, 15 October. Discover his exclusive picks and ...

Dutch health authorities are now monitoring cases of a new COVID-19 variant, named XFG or 'Stratus'. Here's what to look out for. 👀 ...

In nursing homes, neonatal units, and ICU wards, researchers are racing to turn pain into something a camera or sensor can ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

DeepSeek, a blood test that can detect HPV-linked head and neck cancers nearly a decade before diagnosis. By finding viral DNA in the bloodstream, the test achieved 99% sensitivity and specificity.

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting ...

Last week, news stories reported that HHS Secretary Robert F. Kennedy Jr. had convened an "aluminum working group." Among the ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...